← BioTransfer GEO Dataset Finder
GEO series

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

GSE148715 Homo sapiens Expression profiling by high throughput sequencing 38 samples Submitted 2020/05/22 Platform GPL20301
Summary
Seventy-six FDA approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation and transcriptional profiles. We investigated the predictive value of anti-apoptotic BCL2 family member transcriptomic ratios as biomarkers of venetoclax sensitivity. RNA-seq analysis was available in 38 primary patient samples, from which we identified the 9 most (median AUC 0.09409) and least (median AUC 0.7195) sensitive samples to venetoclax.
Published in
"Direct to Drug" screening as a precision medicine tool in multiple myeloma
Bonolo de Campos C, Meurice N, Petit JL et al. · Blood cancer journal 2020 · PMID 32393731 · doi:10.1038/s41408-020-0320-7
This dataset
Download

Direct links to NCBI, no account and no request form: the whole study as GSE148715_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 38 samples. Raw sequencing reads are also available from ENA.

Also filed as BioProject PRJNA627346 and SRA study SRP257861. Searching any of these in the dataset finder brings you back here.

Samples in this study

The sample list for this study is not cached yet. Press Sort into groups and it will be fetched from NCBI.

+ 38 more — browse all 38 samples with per-sample file links →

Similar datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.